-
3 things to know about Reinvent Biologics
Reinvent Biologics is a regenerative medicine company. -
'A new dawn' for orthopedics: Dr. Jason Arora on the promise of biologics
Platelet-rich plasma injections and stem cell therapies are ushering in a "new dawn" in orthopedics, according to Jason Arora, DO, a board-certified interventional spine and pain management physician at West Orange, N.J.-based Atlantic Spine Center. -
Fujifilm, Cynata to collaborate on stem cell therapy trials for transplant patients: 4 insights
Cynata Therapeutics entered into a licensing agreement with Fujifilm Holdings to begin stem cell therapy clinical trials in the U.S. and Japan, according to Nikkei Asian Review. -
Hospital for Special Surgery researchers launch study of Organogenesis' ReNu for knee defects: 5 insights
New York City-based Hospital for Special Surgery researchers launched a clinical trial to assess the effects of Organogenesis' ReNu on knee function. -
Viewpoint: A stem cell provider registry program will improve treatments
A stem cell provider registry program will improve the quality of treatments, wrote Fabio Rossi, MD, PhD, and Judy Illes, PhD, in an op-ed in the Vancouver Sun. -
Baxter receives FDA clearance for posterolateral spinal fusion bone graft substitute: 4 notes
Baxter International received FDA 510(k) clearance for its Altapore Bioactive Bone Graft for spinal fusion. -
3D technology helps identify stem cells in muscle: 3 things to know
Minneapolis-based University of Minnesota Medical School researchers are using 3D technology to identify skeletal muscle stem cells for transplantation, according to Health Data Management. -
Male patients with ankylosing spondylitis respond better to biologics, study finds
Female ankylosing spondylitis patients do not respond as well to biologic treatment as their male counterparts, according to a study presented at the International Congress on Spondyloarthritides 2018 in Gent, Belgium, Oct. 4-8, and reported in Medscape. -
Stem cells 'will change medicine forever' says former surgeon & stem cell expert
Natesh Parashurama, MD, PhD, is a former surgeon and current stem cell researcher. Dr. Parashurama is an assistant chemical and biological engineering professor at the University of Buffalo (N.Y.), where he builds 3D internal organs from human stem cells. -
UT Southwestern launches stem cell trial for rare spinal disorder: 5 things to know
Dallas-based University of Texas Southwestern Medical Center researchers are developing a stem cell-based treatment for a rare spinal cord disorder. -
Mayo Clinic receives $10M donation to support 5 initiatives, including regenerative medicine in spine
The Louis V. Gerstner Jr. Fund at Vanguard Charitable gave Rochester, Minn.-based Mayo Clinic a $10 million grant. -
Heraeus Medical introduces all-in-1 bone cement & vacuum mixing system: 3 insights
Heraeus Medical launched the Palacos R & R+G pro All-in-One Fixation System for the U.S. market. -
4 things to know about Artoss
Artoss is an orthobiologics company. -
InVivo enters new partnership to study spinal scaffold & stem cell combination: 3 notes
InVivo Therapeutics entered into a joint research agreement with Q Therapeutics to evaluate the safety and feasibility of combining InVivo's Neuro-Spinal Scaffold with stem cells. -
Bioventus selects Pfizer as exclusive distribution partner for hip, knee OA solution in Brazil: 3 notes
Bioventus received approval to market Durolane for hip and knee osteoarthritis in Brazil and selected Pfizer as its exclusive distribution partner. -
Orthobiologics company completes 250 cases with OsteoCrete magnesium-based bone void filler: 3 notes
Bone Solutions Inc. announced first 250 cases of its magnesium-based bone void filler OsteoCrete were implanted. -
Maryland Stem Cell Research Fund awards 1st round of $8.2M funding initiative: 5 things to know
Maryland Technology Development Corp., awarded the first two grants from the state's Stem Cell Research Fund, Baltimore Business Journal reports. -
5 things to know about the global orthobiologics market
The global orthobiologics market is projected to grow at a 3.5 percent compound annual growth rate, topping $6.5 billion by 2027, according to a Future Market Insights report. -
Kuros Biosciences appoints 5 spine surgeons to advisory board
Orthobiologics company Kuros Biosciences named its strategic advisory board. -
Orthopedic surgeon named Reinvent Biologics' CMO: 3 insights
Reinvent Biologics appointed orthopedic surgeon David Drez Jr., MD, as CMO.
Page 27 of 34